Showing 1 - 6 results of 6 for search 'Lionel Riou França', query time: 0.03s Refine Results
  1. 1
    Efficacy of avalglucosidase alfa on forced vital capacity percent predicted in treatment-naïve patients with late-onset Pompe disease: A pooled analysis of clinical trials

    Efficacy of avalglucosidase alfa on forced vital capacity percent predicted in treatment-naïve patients with late-onset Pompe disease: A pooled analysis of clinical trials by Tahseen Mozaffar, Lionel Riou França, Jérôme Msihid, Pragya Shukla, Irina Proskorovsky, Tianyue Zhou, Magali Periquet, Kristina An Haack, Laurence Pollissard, Volker Straub

    Published 2024-09-01
    Get full text
    Article
  2. 2
    Applying the win ratio method in clinical trials of orphan drugs: an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease

    Applying the win ratio method in clinical trials of orphan drugs: an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease by Matthias Boentert, Kenneth I. Berger, Jordi Díaz-Manera, Mazen M. Dimachkie, Alaa Hamed, Lionel Riou França, Nathan Thibault, Pragya Shukla, Jack Ishak, J. Jaime Caro

    Published 2024-01-01
    Get full text
    Article
  3. 3
    Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA‐AF registry

    Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA‐AF registry by Changsheng Ma, Lionel Riou França, Shihai Lu, Hans‐Christoph Diener, Sergio J. Dubner, Jonathan L. Halperin, Qiang Li, Miney Paquette, Christine Teutsch, Menno V. Huisman, Gregory Y. H. Lip, Kenneth J. Rothman, the GLORIA‐AF Investigators

    Published 2020-06-01
    Get full text
    Article
  4. 4
    Characteristics and 2‐year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA‐AF

    Characteristics and 2‐year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA‐AF by Sergio J. Dubner, Christine Teutsch, Menno V. Huisman, Hans‐Christoph Diener, Jonathan Halperin, Kenneth J. Rothman, Chang‐Sheng Ma, Eduardo Chuquiure‐Valenzuela, Jutta Bergler‐Klein, Kristina Zint, Lionel Riou França, Shihai Lu, Miney Paquette, Gregory Y.H. Lip

    Published 2020-10-01
    Get full text
    Article
  5. 5
    Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program

    Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program by Lea Beier, Shihai Lu, Lionel Riou França, Sabrina Marler, Gregory Y. H. Lip, Menno V. Huisman, Christine Teutsch, Jonathan L. Halperin, Kristina Zint, Hans-Christoph Diener, Laurie Baker, Chang-Sheng Ma, Miney Paquette, Dorothee B. Bartels, Sergio J. Dubner, Philippe Lyrer, Jochen Senges, Kenneth J. Rothman

    Published 2022-01-01
    Get full text
    Article
  6. 6
    Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program.

    Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program. by Lea Beier, Shihai Lu, Lionel Riou França, Sabrina Marler, Gregory Y H Lip, Menno V Huisman, Christine Teutsch, Jonathan L Halperin, Kristina Zint, Hans-Christoph Diener, Laurie Baker, Chang-Sheng Ma, Miney Paquette, Dorothee B Bartels, Sergio J Dubner, Philippe Lyrer, Jochen Senges, Kenneth J Rothman

    Published 2022-01-01
    Get full text
    Article

Search Tools: